Video

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

Author(s):

Corey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Neil P. Shah, MD, PhD
December 1st 2024

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Lori Muffly, MD
November 29th 2024

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL

Elias Jabbour, MD
November 26th 2024

Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing